Adverse event totals12

The totals the trial posted for each group.

1 to 12 of 12

Total	Group	Affected	At risk
Total, all-cause mortality	Low or Intermediate-1 MDS Group - Lirilumab	0	2
Total, all-cause mortality	Low or Intermediate-1 MDS Group - Nivolumab + Lirilumab	0	0
Total, all-cause mortality	High Risk MDS Group - Azacitidine + Lirilumab	0	8
Total, all-cause mortality	High Risk MDS Group - Azacitidine + Lirilumab + Nivolumab	0	0
Total, other adverse events	Low or Intermediate-1 MDS Group - Lirilumab	1	2
Total, other adverse events	Low or Intermediate-1 MDS Group - Nivolumab + Lirilumab	0	0
Total, other adverse events	High Risk MDS Group - Azacitidine + Lirilumab	8	8
Total, other adverse events	High Risk MDS Group - Azacitidine + Lirilumab + Nivolumab	0	0
Total, serious adverse events	Low or Intermediate-1 MDS Group - Lirilumab	2	2
Total, serious adverse events	Low or Intermediate-1 MDS Group - Nivolumab + Lirilumab	0	0
Total, serious adverse events	High Risk MDS Group - Azacitidine + Lirilumab	7	8
Total, serious adverse events	High Risk MDS Group - Azacitidine + Lirilumab + Nivolumab	0	0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02599649/event-totals